Rothschild, Harriet T.
Clelland, Elle N.
Mujir, Firdows
Record, Helena
Wong, Jasmine
Esserman, Laura J.
Alvarado, Michael
Ewing, Cheryl
Mukhtar, Rita A.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (TL1 TR 001871)
National Cancer Institute (K08CA256047)
Article History
Received: 26 April 2023
Accepted: 4 June 2023
First Online: 18 July 2023
Disclosures
: Dr. Laura Esserman is leading an investigator-initiated vaccine trial for high-risk ductal carcinoma in situ which is funded by Merck through the University of California San Francisco.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the IRB of the University of California, San Francisco (17-23655, January 16, 2020).
: Informed consent requirement was waived by the IRB, as no subjects were contacted for this study.
: Consent for publication was waived by the IRB, as no subjects were contacted for this study.